


Docket No.: 50229-429



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 20277
Jurgen ROHR, et al.	:	Confirmation Number: 9088
Application No.: 10/796,304	:	Group Art Unit: 1645
Filed: March 10, 2004	:	Examiner: Not yet assigned
For: DERIVATIVES OF MITHRAMYCIN AND METHODS OF MAKING AND USES THEREOF		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

10/796,304

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP


Cameron K. Weiffenbach
Registration No. 44,488

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 CKW:blg
Facsimile: 202.756.8087
Date: January 14, 2005

**Please recognize our Customer No. 20277
as our correspondence address.**

SHEET 1 OF 3

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 50229-429		SERIAL NO. 10/796,304	
				APPLICANT Jurgen ROHR, et al.			
				FILING DATE March 10, 2004		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US 3,592,925	07-13-1971	R.H. Evans, JR., et al.			
		US 3,646,194	02-29-1972	B. A. Sobin, et al.			
		US 3,821,085	06-28-1974	Zhdanovich et al.			
		US 3,906,093	09-16-1975	Sobin et al.			
		US 4,141,974	02-27-1979	Davies et al.			
		US 4,452,786	06-05-1984	Mitsuhashi et al.			
		US 4,511,560	04-16-1985	Tomita et al.			
		US 4,935,445	06-19-1990	Merry			
		US 5,057,034	10-15-1991	Kretzschmar et al.			
		US 5,656,736	08-12-1997	Nakano et al.			
		US 5,723,448	03-03-1998	Gross et al.			
		US					
		US					
		US					
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 50229-429		SERIAL NO. 10/796,304	
				APPLICANT Jurgen ROHR, et al.			
				FILING DATE March 10, 2004		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US					
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes -Number -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Lily L. REMSING, et al. "Mithramycin SK, A Novel Antitumor Drug with Improved Therapeutic Index, Mithramycin SA, and Demycarosyl-mithramycin SK: Three New Products Generated in the Mithramycin Producer <i>Streptomyces argillaceus</i> through Combinatorial Biosynthesis" J. AM. CHEM. SOC. 2003, 125, pp. 5745-5753					
		Robert J. FERRANTE, et al. "Chemotherapy for the Brain: Mithramycin Prolongs Survival in a Model of Huntington's Disease"					
		L. PRADO, et al. "Analysis of two chromosomal regions adjacent to genes for a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in <i>Streptomyces argillaceus</i> ." 1: Mol Gen Genet. 1999 Mar;261(2):216-25.					
		G. BLANCO, et al. "Characterization of two glycosyltransferases involved in early glycosylation steps during biosynthesis of the antitumor polyketide mithramycin by <i>Streptomyces argillaceus</i> ." 1: Mol Gen Genet. 2000 Jan;262(6):991-1000.					
		MJ LOZANO, et al. "Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by <i>Streptomyces argillaceus</i> ." 1: J Biol Chem. 2000 Feb 4;275(5):3065-74.					
		J. KANTOLA, et al. "Folding of the polyketide chain is not dictated by minimal polyketide synthase in the biosynthesis of mithramycin and anthracycline." 1: Chem Biol. 1997 Oct;4(10):751-5.					
		L. PRADO, et al. "Oxidative cleavage of premithramycin B is one of the last steps in the biosynthesis of the antitumor drug mithramycin." 1: Chem Biol. 1999 Jan;6(1):19-30.					
		E. FERNANDEZ, et al. "Identification of two genes from <i>Streptomyces argillaceus</i> encoding glycosyltransferases involved in transfer of a disaccharide during biosynthesis of the antitumor drug mithramycin." 1: J Bacteriol. 1998 Sep;180(18):4929-37.					
		D RODRIGUEZ, et al. "Purification and characterization of a monooxygenase involved in the biosynthetic pathway of the antitumor drug mithramycin." 1: J Bacteriol. 2003 Jul;185(13):3962-5.					
		D RODRIGUEZ, et al. "MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction." 1: J Biol Chem. 2003 Dec 5 [Epub ahead of print].					
		A. GONZALEZ, et al. "The mtmVUC genes of the mithramycin gene cluster in <i>Streptomyces argillaceus</i> are involved in the biosynthesis of the sugar moieties." MOLECULAR AND GENERAL GENETICS, (FEB 2001) Vol. 264, No. 6, pp. 827-835. SPRINGER-VERLAG, New York.					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 50229-429		SERIAL NO. 10/796,304	
				APPLICANT Jurgen ROHR, et al.			
				FILING DATE March 10, 2004		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US					
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Lily L REMSING, et al. "Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by <i>Streptomyces argillaceus</i> , reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2002 Feb 27) 124 (8) 1606-14.					
		Axel TREFZER, et al. "Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2002 May 29) 124 (21) 6056-62.					
		J. PLOWMAN, et al. "Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture and in mice." CANCER RESEARCH, (1995 Feb 15) 55 (4) 862-7.					
		P. H. VIOLIER, et al. "Role of acid metabolism in <i>Streptomyces coelicolor</i> morphological differentiation and antibiotic biosynthesis." JOURNAL OF BACTERIOLOGY, (2001 May) 183 (10) 3184-92.					
		Lily L REMSING, et al. "Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target." BIOCHEMISTRY, (2003 Jul 15) 42 (27) 8313-24.					
		K. STAJNER, et al. "Variability and strain selection in <i>Streptomyces atroolivaceus</i> . II. Chromatographic analysis of mithramycin-producing and nonproducing strains." Folia Microbiologica (Prague, Czech Republic) (1974), 19(6), 498-506.					
		G. BLANCO, et al. "Identification of a sugar flexible glycosyltransferase from <i>Streptomyces olivaceus</i> , the producer of the antitumor polyketide elloramycin." CHEMISTRY AND BIOLOGY, (2001 Mar) 8 (3) 253-63.					
		M J F LOZANO, et al. "Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by <i>Streptomyces argillaceus</i> ." JOURNAL OF BIOLOGICAL CHEMISTRY, (4 FEB 2000) Vol. 275, No. 5, pp. 3065-3074. Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, Bethesda, MD.					
		Lily L. REMSING, et al. "Mithramycin SK, a novel aureolic acid-type antitumor compound generated by combinatorial biosynthesis, shows an improved therapeutic index compared to mithramycin in <i>in vitro</i> antitumor and toxicity assays." 2003, American Association for Cancer Research. 2003 Proceedings of the AACR < http://aacr03.agora.com/planner/displayabstract.asp?presentationid=9968 >					
		Sukalyan CHATTERJEE, PhD, et al. "Sequence-Selective DNA Binding Drugs Mithramycin A and Chromomycin A ₃ Are Potent Inhibitors of Neuronal Apoptosis Induced by Oxidative Stress and DNA Damage in Cortical Neurons." Annals of Neurology, Vol. 49, No. 3, March 2001, Wiley-Liss, Inc., pp. 345-354.					
		Lily L. REMSING, et al. "Ketopremithramycins and Ketomithramycins, Four New Aureolic Acid-Type Compounds Obtained upon Inactivation of Two Genes Involved in the Biosynthesis of the Deoxysugar Moieties of the Antitumor Drug Mithramycin by <i>Streptomyces Argillaceus</i> , Reveal Novel Insights into Post-PKS Tailoring Steps of the Mithramycin Biosynthetic Pathway." J. AM. CHEM. SOC., Vol. 124, No. 8, 2002, pp. 1606-1614.					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.